Publications

Export 92 results:
Auteur [ Title(Desc)] Type Année
Filtres: Auteur is Pedro Rosa-Neto  [Enlever les filtres]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
1
Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim H-I, Gauthier S, Pellerin L, Hamel E, Rosa-Neto P.  2017.  [(18)F]FDG PET signal is driven by astroglial glutamate transport.. Nat Neurosci. 20(3):393-395.
Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, Tissot C, Qureshi MNaveed Iqb, Kang MSu, Mathotaarachchi S et al..  2020.  18F-MK-6240 PET for early and late detection of neurofibrillary tangles.. Brain. 143(9):2818-2830.
A
Pascoal TA, Mathotaarachchi S, Shin M, Park AYeon, Mohades S, Benedet AL, Kang MSu, Massarweh G, Soucy J-P, Gauthier S et al..  2018.  Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.. Eur J Nucl Med Mol Imaging. 45(6):1021-1030.
Kang MSu, Aliaga AAliaga, Shin M, Mathotaarachchi S, Benedet AL, Pascoal TA, Therriault J, Chamoun M, Savard M, Devenyi GA et al..  2020.  Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease.. Mol Psychiatry.
Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung C-O, Shin M, Wang S, Beaudry T, Kang MS, Soucy J-P et al..  2016.  Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.. Mol Psychiatry.
Ongali B, Nicolakakis N, Tong X-K, Aboulkassim T, Papadopoulos P, Rosa-Neto P, Lecrux C, Imboden H, Hamel E.  2014.  Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model.. Neurobiol Dis. 68:126-36.
Therriault J, Ng KPin, Pascoal TA, Mathotaarachchi S, Kang MSu, Struyfs H, Shin M, Benedet AL, Walpola IC, Nair V et al..  2018.  Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.. Neurology. 90(11):e932-e939.
Ba M, Kong M, Li X, Ng KPin, Rosa-Neto P, Gauthier S.  2016.  Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 5:20.
Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Savard M, Chamoun M, Thomas É, Kang MSu, Lussier F, Tissot C et al..  2020.  APOEε4 potentiates the relationship between amyloid-β and tau pathologies.. Mol Psychiatry.
Miron J, Picard C, Lafaille-Magnan M-E, Savard M, Labonte A, Breitner JCS, Rosa-Neto P, Auld D, Poirier J.  2019.  Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation.. Alzheimers Dement. 15(7):951-960.
Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER.  2019.  Astrocyte Biomarkers in Alzheimer's Disease.. Trends Mol Med.
Gauthier S, Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedetti AL, Shin M, Kang MSu, Li X, Ba M et al..  2017.  Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 89(18):1931.
Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P et al..  2019.  Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.. Nat Commun. 10(1):2240.
B
Meyer P-F, Savard M, Poirier J, Labonte A, Rosa-Neto P, Weitz TM, Town T, Breitner JCS.  2018.  Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.. J Alzheimers Dis. 63(2):577-590.
C
Laforce R, Rosa-Neto P, Soucy J-P, Rabinovici GD, Dubois B, Gauthier S.  2016.  Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
DuBois JM, Rousset OG, Rowley J, Porras-Betancourt M, Reader AJ, Labbe A, Massarweh G, Soucy J-P, Rosa-Neto P, Kobayashi E.  2016.  Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [(11)C]ABP688 PET.. Eur J Nucl Med Mol Imaging. 43(1):152-62.
Li X, Ba M, Ng KPin, Mathotaarachchi S, Pascoal TA, Rosa-Neto P, Gauthier S.  2018.  Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.. Alzheimers Dement (Amst). 10:12-21.
[Anonymous].  2020.  Cholinergic dysfunction in the dorsal striatum promotes habit formation and maladaptive eating.. J Clin Invest. 130(12):6616-6630.
Sheynin Y, Rosa-Neto P, Hess RF, Vaucher E.  2020.  Cholinergic Modulation of Binocular Vision.. J Neurosci. 40(27):5208-5213.
Chamoun M, Huppé-Gourgues F, Legault I, Rosa-Neto P, Dumbrava D, Faubert J, Vaucher E.  2017.  Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three Dimensional Multiple Object Tracking.. Front Hum Neurosci. 11:128.
Tam A, Dansereau C, Badhwar AP, Orban P, Belleville S, Chertkow H, Dagher A, Hanganu A, Monchi O, Rosa-Neto P et al..  2015.  Common Effects of Amnestic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies.. Front Aging Neurosci. 7:242.
Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D et al..  2017.  Consensus guidelines for lumbar puncture in patients with neurological diseases.. Alzheimers Dement (Amst). 8:111-126.
Jiang L, Oualkacha K, Didelez V, Ciampi A, Rosa-Neto P, Benedet AL, Mathotaarachchi S, Richards JBrent, Greenwood CMT.  2019.  Constrained instruments and their application to Mendelian randomization with pleiotropy.. Genet Epidemiol.
D
Tam A, Dansereau C, Badhwar AP, Orban P, Belleville S, Chertkow H, Dagher A, Hanganu A, Monchi O, Rosa-Neto P et al..  2016.  A dataset of multiresolution functional brain parcellations in an elderly population with no or mild cognitive impairment.. Data Brief. 9:1122-1129.
Tuwaig M, Savard M, Jutras B, Poirier J, D Collins L, Rosa-Neto P, Fontaine D, Breitner JCS.  2017.  Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease.. J Alzheimers Dis. 60(4):1589-1600.

Pages